NEWTON,
Mass., Jan. 4, 2023 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate at the
41st Annual J.P. Morgan Healthcare Conference in a
podium presentation on Wednesday, January
11 at 10:30 a.m. PT, followed
by a question-and-answer breakout session at 10:50 a.m. PT.
A live webcast of the presentation, along with accompanying
slides, can be accessed under "Events & Presentations" in the
Investor section of the Company's
website, http://investors.karyopharm.com/events-presentations,
and will be available for replay for 30 days following the
event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and
marketed by the Company in three oncology indications and has
received regulatory approvals in various indications in a growing
number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline
targeting multiple high unmet need cancer indications, including in
multiple myeloma, endometrial cancer, myelodysplastic syndromes and
myelofibrosis. For more information about our people, science and
pipeline, please visit www.karyopharm.com, and follow us on Twitter
at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm
Therapeutics Inc. Any other trademarks referred to in this release
are the property of their respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-41st-annual-jp-morgan-healthcare-conference-301712627.html
SOURCE Karyopharm Therapeutics Inc.